KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Non-Current Debt (2017 - 2026)

Aquestive Therapeutics has reported Non-Current Debt over the past 9 years, most recently at $27.5 million for Q4 2025.

  • For Q4 2025, Non-Current Debt fell 15.33% year-over-year to $27.5 million; the TTM value through Dec 2025 reached $27.5 million, down 15.33%, while the annual FY2025 figure was $27.5 million, 15.33% down from the prior year.
  • Non-Current Debt for Q4 2025 was $27.5 million at Aquestive Therapeutics, down from $29.9 million in the prior quarter.
  • Over five years, Non-Current Debt peaked at $51.6 million in Q4 2021 and troughed at $16.1 million in Q1 2024.
  • A 5-year average of $32.9 million and a median of $32.6 million in 2021 define the central range for Non-Current Debt.
  • Biggest five-year swings in Non-Current Debt: tumbled 52.53% in 2023 and later soared 109.36% in 2025.
  • Year by year, Non-Current Debt stood at $51.6 million in 2021, then plummeted by 35.12% to $33.4 million in 2022, then fell by 17.76% to $27.5 million in 2023, then grew by 18.15% to $32.5 million in 2024, then dropped by 15.33% to $27.5 million in 2025.
  • Business Quant data shows Non-Current Debt for AQST at $27.5 million in Q4 2025, $29.9 million in Q3 2025, and $31.8 million in Q2 2025.